MaxCyte, Inc. (MXCT) SEC Filings & Earnings Calls

Preliminary results are unaudited and subject to change; actual results may differ.

“These results remain subject to completion of the Company’s quarter-end closing procedures and review of its interim financial statements.” · word for word

Concentration risk from large customer accelerated purchasing; sustainability uncertain.

“accelerated instrument purchasing from a large customer, which we originally anticipated to occur in the fourth quarter” · word for word

Core revenue decline and partner program discontinuations

“License revenue declined primarily due to the discontinuation of a few partner programs.” · word for word

Dependence on customer capital availability

“changes in the amount of capital available to existing and emerging customers in our target markets” · word for word

Core revenue decline indicates potential market share loss or demand weakness.

“Core revenue down 21% YoY.”

Customer concentration risk

“Customer A 34% and Customer B 22% of revenue for the three months ended March 31, 2026.”

Core revenue decline risk

“Total core revenue $6,218 and $8,243 for the three months ended March 31, 2026 and 2025, respectively.”

Core revenue decline of 25% YoY indicates potential demand weakness in instruments and consumables.

“Core business revenue of $6.2 million in Q1 2026, a decrease of 25% over Q1 2025.”

Key executive transition (CFO departure)

“Mr. Swirsky will transition from his position as Chief Financial Officer of the Company, effective as of the earlier of May 31, 2026 and the appointment of a new Chief Financial Officer” · word for word

Former CCO termination

“On August 11, 2025, Mr. Soleymannezhad’s employment with the Company was terminated without cause” · word for word

Customer concentration

“For the year ended December 31, 2025, one cell therapy company with which we have entered into an SPL agreement accounted for 26% of our total revenue, and our five largest customers accounted for an aggregate of approximately 42% of our total revenue.” · word for word

Nasdaq minimum bid price non-compliance

“On March 16, 2026, we received notice from the Listing Qualifications staff of The Nasdaq Stock Market LLC ('Nasdaq') that, because the closing bid price for our common stock had fallen below $1.00 per share for 30 consecutive trading days, we no longer complied with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market u” · word for word

Continued operating losses

“We have incurred significant losses since inception and have financed our operations principally through private financings and public offerings of our securities.” · word for word

Dependence on SPL customer clinical success

“Our customers may not achieve projected development and regulatory milestones and other anticipated key events in the expected timelines or at all, or may discontinue some or all of their programs, which could have an adverse impact on our business and could cause the price of our common stock to decline.” · word for word

Customer concentration risk: 15% reduction from largest customer impacting revenue.

“15% reduction in purchases and leases from our largest customer.” · word for word

Declining SPL program-related revenue (-44% YoY) and clinical programs under SPLs (13 vs 18).

“SPL Program-related revenue was $3.4 million for the full year 2025, compared to $6.1 million in full year 2024.” · word for word

FY2026 revenue guidance below FY2025 actual, indicating continued headwinds.

“Expects 2026 revenue of $30-32 million vs FY2025 $33.0 million.”

SPL customer rationalization and inventory management could continue to pressure revenue.

“rationalization of programs and inventory management from a few SPL customers” · word for word

Preliminary results subject to change upon completion of closing procedures.

“preliminary, unaudited and subject to change” · word for word

Core Revenue Decline

“Total core revenue for the three months ended September 30, 2025 was $6.4 million, a decrease of $1.7 million, or 21%, compared to the three months ended September 30, 2024.” · word for word

Restructuring Execution Risk

“The Plan is expected to result in a reduction of approximately 34% of the Company’s workforce globally.” · word for word

Customer Concentration

“During the three months ended September 30, 2025, one customer represented 28% of revenue.” · word for word

Revenue decline across all core segments; cell therapy funding environment remains challenging.

“Core revenue -21% YoY; instruments -22%, consumables -25%, licenses -29%.”

Non-GAAP gross margin compression; restructuring may impact near-term growth.

“Non-GAAP adjusted gross margin 81% vs 85%; restructuring announced.”

Core revenue decline across all segments indicates demand weakness in cell engineering tools.

“Core revenue -21% YoY; instruments -22%, PAs/consumables -25%, licenses -29%.”

Cash burn from operational restructuring reduces financial flexibility.

“Cash guidance revised to $152-155M from prior expectation; reflects near-term cash utilization from restructuring.”

Potential goodwill or long-lived asset impairment testing may indicate asset write-down risk.

“Company rescheduled earnings to complete review of goodwill and long-lived asset impairment testing.”